Medtronic said Monday it plans to acquire Contego Medical, a privately held medical device company focused on technologies for carotid artery disease and peripheral thrombectomy.
The transaction is valued at $380 million, with potential payments post-acquisition.
The deal will expand Medtronic’s portfolio of carotid disease treatments and build on the company’s exclusive U.S. distribution agreement with Contego, announced in January 2025.
When the carotid arteries supplying blood to the brain become narrowed or blocked, plaque can rupture or embolize and lead to a stroke. Contego’s products include the Neuroguard IEP carotid stent system, which is designed with embolic protection to catch small particles including clots that can block blood vessels.
Pairing its clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments, Medtronic expects to become “an undisputed leader in carotid revascularization," David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, said in a statement.
Contego’s portfolio also includes the Excipio thrombectomy device, which complements Medtronic's Liberant thrombectomy system to treat peripheral vascular disease, Medtronic said.
Medtronic has been a minority investor in Contego since 2020.
The company expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. The acquisition is expected to be minimally dilutive to Medtronic’s adjusted earnings per share in fiscal 2027 and 2028, then neutral to accretive after that.